208 related articles for article (PubMed ID: 9369533)
21. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis.
Hitchon CA; Danning CL; Illei GG; El-Gabalawy HS; Boumpas DT
J Rheumatol; 2002 Jan; 29(1):107-17. PubMed ID: 11824946
[TBL] [Abstract][Full Text] [Related]
22. Matrix metalloproteinase 9 (MMP-9) is upregulated during scarless wound healing in athymic nude mice.
Manuel JA; Gawronska-Kozak B
Matrix Biol; 2006 Oct; 25(8):505-14. PubMed ID: 17010584
[TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinases and their inhibitors in gastric cancer.
Murray GI; Duncan ME; Arbuckle E; Melvin WT; Fothergill JE
Gut; 1998 Dec; 43(6):791-7. PubMed ID: 9824606
[TBL] [Abstract][Full Text] [Related]
24. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid.
Niimi Y; Pawankar R; Kawana S
Int Arch Allergy Immunol; 2006; 139(2):104-13. PubMed ID: 16374020
[TBL] [Abstract][Full Text] [Related]
25. Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases.
Fukuda Y; Ishizaki M; Kudoh S; Kitaichi M; Yamanaka N
Lab Invest; 1998 Jun; 78(6):687-98. PubMed ID: 9645759
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy.
Leppert D; Hughes P; Huber S; Erne B; Grygar C; Said G; Miller KM; Steck AJ; Probst A; Fuhr P
Neurology; 1999 Jul; 53(1):62-70. PubMed ID: 10408538
[TBL] [Abstract][Full Text] [Related]
27. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers.
Nwomeh BC; Liang HX; Cohen IK; Yager DR
J Surg Res; 1999 Feb; 81(2):189-95. PubMed ID: 9927539
[TBL] [Abstract][Full Text] [Related]
28. In situ gelatinolytic activity correlates with tumor progression and prognosis in patients with bladder cancer.
Kawamura K; Kamiya N; Suyama T; Shimbo M; Oosumi N; Suzuki H; Ueda T; Tobe T; Igarashi T; Ito H; Ishikura H
J Urol; 2004 Oct; 172(4 Pt 1):1480-4. PubMed ID: 15371875
[TBL] [Abstract][Full Text] [Related]
29. Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds.
Agren MS; Mirastschijski U; Karlsmark T; Saarialho-Kere UK
Exp Dermatol; 2001 Oct; 10(5):337-48. PubMed ID: 11589731
[TBL] [Abstract][Full Text] [Related]
30. Characterization of matrix metalloproteinases in human urine: alterations during adolescence.
Thrailkill KM; Kumar S; Rosenberg CK; Auten KJ; Fowlkes JL
Pediatr Nephrol; 1999 Apr; 13(3):223-9. PubMed ID: 10353410
[TBL] [Abstract][Full Text] [Related]
31. Proteinases, their inhibitors, and cytokine profiles in acute wound fluid.
Baker EA; Leaper DJ
Wound Repair Regen; 2000; 8(5):392-8. PubMed ID: 11115151
[TBL] [Abstract][Full Text] [Related]
32. 92K-GL (MMP-9) and 72K-GL (MMP-2) are produced in vivo by human oral squamous cell carcinomas and can enhance FIB-CL (MMP-1) activity in vitro.
Pickett KL; Harber GJ; DeCarlo AA; Louis P; Shaneyfelt S; Windsor LJ; Bodden MK
J Dent Res; 1999 Jul; 78(7):1354-61. PubMed ID: 10403463
[TBL] [Abstract][Full Text] [Related]
33. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients.
Lobmann R; Ambrosch A; Schultz G; Waldmann K; Schiweck S; Lehnert H
Diabetologia; 2002 Jul; 45(7):1011-6. PubMed ID: 12136400
[TBL] [Abstract][Full Text] [Related]
34. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis.
Kossakowska AE; Edwards DR; Lee SS; Urbanski LS; Stabbler AL; Zhang CL; Phillips BW; Zhang Y; Urbanski SJ
Am J Pathol; 1998 Dec; 153(6):1895-902. PubMed ID: 9846979
[TBL] [Abstract][Full Text] [Related]
35. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas.
Nomura H; Fujimoto N; Seiki M; Mai M; Okada Y
Int J Cancer; 1996 Feb; 69(1):9-16. PubMed ID: 8600068
[TBL] [Abstract][Full Text] [Related]
36. Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with N-nitrosobis(2-oxopropyl)amine.
Iki K; Tsutsumi M; Kido A; Sakitani H; Takahama M; Yoshimoto M; Motoyama M; Tatsumi K; Tsunoda T; Konishi Y
Carcinogenesis; 1999 Jul; 20(7):1323-9. PubMed ID: 10383907
[TBL] [Abstract][Full Text] [Related]
37. Expression of matrix metalloproteinases and their endogenous tissue inhibitors in skin lesions from patients with tuberous sclerosis.
Papakonstantinou E; Dionyssopoulos A; Aletras AJ; Pesintzaki C; Minas A; Karakiulakis G
J Am Acad Dermatol; 2004 Oct; 51(4):526-33. PubMed ID: 15389186
[TBL] [Abstract][Full Text] [Related]
38. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair.
Soo C; Shaw WW; Zhang X; Longaker MT; Howard EW; Ting K
Plast Reconstr Surg; 2000 Feb; 105(2):638-47. PubMed ID: 10697171
[TBL] [Abstract][Full Text] [Related]
39. Expression of membrane-type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage.
Imai K; Ohta S; Matsumoto T; Fujimoto N; Sato H; Seiki M; Okada Y
Am J Pathol; 1997 Jul; 151(1):245-56. PubMed ID: 9212749
[TBL] [Abstract][Full Text] [Related]
40. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.
Paju A; Sorsa T; Tervahartiala T; Koivunen E; Haglund C; Leminen A; Wahlström T; Salo T; Stenman UH
Br J Cancer; 2001 May; 84(10):1363-71. PubMed ID: 11355948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
